Kymera Therapeutics Inc. has unveiled a corporate presentation detailing their advancements in the field of immunology through the use of oral medicines. The company is a leader in Targeted Protein Degradation $(TPD.AU)$ and has developed best-in-industry capabilities for creating oral degraders. Kymera is focused on targeting traditionally undrugged targets in validated pathways, aiming to disrupt conventional treatment paradigms. With a robust portfolio, Kymera aims to deliver oral therapies with biologics-like profiles, potentially expanding access to millions of patients worldwide. The presentation highlighted that since 2020, Kymera has brought five new investigational degrader drugs into the clinic and plans to introduce a total of ten by 2026. They have already dosed over 400 healthy volunteers and patients, demonstrating strong clinical activity and desired tolerability across all programs. The company sees an enormous untapped market in immunology, with plans to displace injectable biologics and address the needs of the 97% of patients who are unserved or underserved by current advanced therapies. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.